Promising therapeutic targets for ischemic stroke identified from plasma and cerebrospinal fluid proteomes: A multicenter mendelian randomization study

Author:

Zou Xuelun1,Wang Leiyun2,Wang Sai1,Zhang Yupeng1,Ma Junyi1,Chen Lei1,Li Ye1,Yao Tian-Xing1,Zhou Huifang1,Wu Lianxu1,Tang Qiaoling1,Ma Siyuan1,Zhang Xiangbin1,Tang Rongmei1,Yi Yexiang1,Liu Ran1,Zeng Yi3,Zhang Le14567

Affiliation:

1. Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan,410008, P.R. China

2. Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, Hubei, China

3. Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, P.R. China

4. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P.R. China

5. Multi-Modal Monitoring Technology for Severe Cerebrovascular Disease of Human Engineering Research Center, Xiangya Hospital, Central South University

6. Brain Health Center of Hunan Province, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P.R. China

7. Human Brain Disease Biological Resources Platform of Hunan Province, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P.R. China

Abstract

Background: Ischemic stroke (IS) is more common every year, the condition is serious, and have a poor prognosis. New, efficient, and safe therapeutic targets are desperately needed as early treatment especially prevention and reperfusion is the key to lowering the occurrence of poorer prognosis. Generally circulating proteins are attractive therapeutic targets, this study aims to identify potential pharmacological targets among plasma and cerebrospinal fluid (CSF) proteins for the prevention and treatment of IS using a multicenter Mendelian randomization (MR) approach. Methods: First, the genetic instruments of 734 plasma and 151 CSF proteins were assessed for causative connections with IS from MEGASTROKE consortium by MR to identify prospective therapeutic targets. Then, for additional validation, plasma proteins from the deCODE consortium and the Fenland consortium, as well as IS GWAS data from the FinnGen cohort, the ISGC consortium and UK biobank, were employed. A thorough evaluation of the aforementioned possible pharmacological targets was carried out using meta-analysis. The robustness of MR results was then confirmed through sensitivity analysis using several techniques, such as bidirectional MR analysis, Steiger filtering, and Bayesian co-localization. Finally, methods like Protein-Protein Interaction (PPI) Networking were utilized to investigate the relationship between putative drug targets and therapeutic agents. Results: We discovered 3 proteins that may function as promising therapeutic targets for IS and meet the Bonferroni correction (P<0.05/885=5.65×10-5). Prekallikrein (OR=0.41, 95%CI: 0.27-0.63, P=3.61×10-5), a protein found in CSF, has a 10-fold protective impact in IS, while the plasma proteins SWAP70 (OR=0.85, 95%CI: 0.80-0.91, P=1.64×10-6) and MMP-12 (OR=0.92, 95%CI: 0.89-0.95, P=4.49×10-6) of each SD play a protective role in IS. Prekallikrein, MMP-12, SWAP70 was replicated in the FinnGen cohort and ISGC database. MMP-12 (OR=0.93, 95%CI: 0.91-0.94, P<0.001), SWAP70 (OR=0.92, 95%CI: 0.90-0.94, P<0.001), and prekallikrein (OR=0.53, 95%CI: 0.33-0.72, P<0.001) may all be viable targets for IS, according to the combined meta-analysis results. Additionally, no evidence of reverse causality was identified, and Bayesian co-localization revealed MMP-12 (PPH4=0.995), SWAP70(PPH4=0.987) and prekallikrein(PPH4=0.894) shared the same variant with IS, supporting the robustness of the aforementioned causation. Prekallikrein and MMP-12 were associated with the target protein of the current treatment of IS. Among them, Lanadelumab, a new drug whose target protein is a prekallikrein, may be a promising new drug for the treatment of IS. Conclusion: The prekallikrein, MMP-12 and SWAP70 are causally associated with the risk of IS. Moreover, MMP-12 and prekallikrein may be treated as promising therapeutic targets for medical intervention of IS.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3